Health
BioVaxys Files Patent Application for Novel COVID-19 Diagnostic for T-Cell Immunity – Yahoo Finance
Vancouver, British Columbia–(Newsfile Corp. – November 2, 2020) – BioVaxys Technology Corp. (CSE: BIOV) (“BioVaxys” or “the Company”), a world leader in…
Vancouver, British Columbia–(Newsfile Corp. – November 2, 2020) – BioVaxys Technology Corp. (CSE: BIOV) (“BioVaxys” or “the Company”), a world leader in haptenized protein vaccine research and development, announced today that it has filed a Provisional Patent Application with the U.S. Patent and Trademark Office entitled METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE RESPONSE related to the potential development of a diagnostic for evaluating the presence or absence of a T-cell immune response…
-
General11 hours agoRSL NSW president Mick Bainbridge and three board members resign in wake of 7.30 investigation into conflicts of interest
-
General14 hours agoSelf-taught child drummer makes rock band debut with The Living End
-
Noosa News18 hours agoWave of cruises headed for Sunshine Coast this summer
-
General22 hours agoNewsCorp executive warns AI firms are asking Australia to ‘surrender our stories’